Diagnosis and treatment of hypereosinophilic syndromes

被引:35
作者
Fletcher, Sarah
Bain, Barbara
机构
[1] St Marys Hosp, Dept Haematol, London W2 1NY, England
[2] St Marys Hosp, Imperial Coll, Fac Med, London W2 1NY, England
关键词
eosinophilia; eosinophilic leukemia; hypereosinophilic syndromes; tyrosine kinase inhibitors;
D O I
10.1097/00062752-200701000-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review The aim of this article is to provide an update of causes of hypereosinophilia, including advances in knowledge of eosinophilic leukemia, and to outline an approach to investigation. We also aim to discuss in more detail the diagnosis and management of various hypereosinophilic syndromes including the clonal eosinophilias and those driven by abnormal cytokine-secreting T cells. Recent findings Our understanding of the causative genetic abnormalities in eosinophilic leukemia is increasing, as is the repertoire of techniques available to detect them. New treatments on the horizon include further tyrosine kinase inhibitors for use in eosinophilic leukemia, which should provide an alternative to imatinib for those patients who develop resistance. These may also prove useful for other hypereosinophilic syndromes without PDGFRA or PDGFRB rearrangements. Other new therapies including anti-IL5 monoclonal antibodies are proving beneficial for some patients, especially those with abnormal T-cell populations. Summary As our understanding of the various hypereosinophilic syndromes increases, and we are able to characterize many of the causative genetic lesions in the clonal eosinophilias, we are increasingly able to select appropriate therapy for an individual patient. New therapies based on this knowledge should serve to further improve the prognosis for many patients with hypereosinophilia.
引用
收藏
页码:37 / 42
页数:6
相关论文
共 33 条
[1]   Cytogenetic and molecular genetic aspects of eosinophilic leukaemias [J].
Bain, BJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (02) :173-179
[2]   Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis [J].
Bain, BJ .
AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (01) :82-85
[3]  
BAIN BJ, 2002, BLOOD CELLS PRACTICA, P192
[4]  
BAIN BJ, 2004, HAEMATOLOGICA, V89, P238
[5]   The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA [J].
Baxter, EJ ;
Hochhaus, A ;
Bolufer, P ;
Reiter, A ;
Fernandez, JM ;
Senent, L ;
Cervera, J ;
Moscardo, F ;
Sanz, MA ;
Cross, NCP .
HUMAN MOLECULAR GENETICS, 2002, 11 (12) :1391-1397
[6]   Interferon-α in the idiopathic hypereosinophilic syndrome:: consideration of five cases [J].
Ceretelli, S ;
Capochiani, E ;
Petrini, M .
ANNALS OF HEMATOLOGY, 1998, 77 (04) :161-164
[7]   PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder [J].
Chen, J ;
DeAngelo, DJ ;
Kutok, JL ;
Williams, IR ;
Lee, BH ;
Wadleigh, M ;
Duclos, N ;
Cohen, S ;
Adelsperger, J ;
Okabe, R ;
Coburn, A ;
Galinsky, I ;
Huntly, B ;
Cohen, PS ;
Meyer, T ;
Fabbro, D ;
Roesel, J ;
Banerji, L ;
Griffin, JD ;
Xiao, S ;
Fletcher, JA ;
Stone, RM ;
Gilliland, DG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (40) :14479-14484
[8]   Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity [J].
Chung, KF ;
Hew, M ;
Score, J ;
Jones, AV ;
Reiter, A ;
Cross, NCP ;
Bain, BJ .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (01) :230-232
[9]   PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease [J].
Cools, J ;
Stover, EH ;
Boulton, CL ;
Gotlib, J ;
Legare, RD ;
Amaral, SM ;
Curley, DP ;
Duclos, N ;
Rowan, R ;
Kutok, JL ;
Lee, BH ;
Williams, IR ;
Coutre, SE ;
Stone, RM ;
DeAngelo, DJ ;
Marynen, P ;
Manley, PW ;
Meyer, T ;
Fabbro, D ;
Neuberg, D ;
Weisberg, E ;
Griffin, JD ;
Gilliland, DG .
CANCER CELL, 2003, 3 (05) :459-469
[10]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214